Predictors of Liver Fat and Stiffness in Non-Alcoholic Fatty Liver Disease (NAFLD) - An 11-Year Prospective Study

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Lallukka, Susanna ^a,b   Sädevirta, Sanja ^a,b   Kallio, Markus T ^a,b   Luukkonen, Panu K ^a,b   Zhou, You ^a,c   Hakkarainen, Antti ^d   Lundbom, Nina ^d   Orho Melander, Marju ^e   Yki Järvinen, Hannele ^a,b  

^a MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; FATTY LIVER; FEMALE; HUMAN; INSULIN RESISTANCE; LIVER; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PATHOLOGY; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 85033448661     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-14706-0     Document Type: Article

References (48)

1. European Association for the Study of Diabetes, European Association for the Study of Diabetes & European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388-1402 (2016).
2. Teli, M. R., James, O. F., Burt, A. D., Bennett, M. K. & Day, C. P. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 22, 1714-1719 (1995).
3. Pais, R. et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J. Hepatol. 59, 550-556 (2013).
4. Wong, V. W. et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 59, 969-974 (2010).
5. McPherson, S. et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J. Hepatol. 62, 1148-1155 (2015).
6. Singh, S. et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin. Gastroenterol. Hepatol. 13, 643-54.e1-9; quiz e39-40 (2015).
7. Jungermann, K. & Kietzmann, T. Oxygen: modulator of metabolic zonation and disease of the liver. Hepatology 31, 255-260 (2000).
8. Nath, B. & Szabo, G. Hypoxia and hypoxia inducible factors: diverse roles in liver diseases. Hepatology 55, 622-633 (2012).
9. Kotronen, A., Westerbacka, J., Bergholm, R., Pietilainen, K. H. & Yki-Jarvinen, H. Liver fat in the metabolic syndrome. J. Clin. Endocrinol. Metab. 92, 3490-3497 (2007).
10. Ratziu, V. et al. Fibrogenic impact of high serum glucose in chronic hepatitis C. J. Hepatol. 39, 1049-1055 (2003).
11. Simons, N. et al. PNPLA3, TM6SF2, and MBOAT7 Genotypes and Coronary Artery Disease. Gastroenterology 152, 912-913 (2017).
12. Kozlitina, J. et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 46, 352-356 (2014).
13. Mancina, R. M. et al. The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. Gastroenterology 150, 1219-1230.e6 (2016).
14. Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40, 1461-1465 (2008).
15. Wong, V. W. et al. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J. Hepatol. 62, 182-189 (2015).
16. Kim, G. et al. Longitudinal effects of MRI-measured hepatic steatosis on biomarkers of glucose homeostasis and hepatic apoptosis in obese youth. Diabetes Care 36, 130-136 (2013).
17. European Association for Study of Liver & Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J. Hepatol. 63, 237-264 (2015).
18. Boursier, J. et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J. Hepatol. 65, 570-578 (2016).
19. Makkonen, J. et al. Increased expression of the macrophage markers and of 11beta-HSD-1 in subcutaneous adipose tissue, but not in cultured monocyte-derived macrophages, is associated with liver fat in human obesity. Int. J. Obes. (Lond) 31, 1617-1625 (2007).
20. Juurinen, L., Tiikkainen, M., Hakkinen, A. M., Hakkarainen, A. & Yki-Jarvinen, H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 292, E829-35 (2007).
21. Ryysy, L. et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49, 749-758 (2000).
22. Seppala-Lindroos, A. et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endocrinol. Metab. 87, 3023-3028 (2002).
23. Vehkavaara, S. et al. Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 20, 545-550 (2000).
24. Westerbacka, J. et al. Acute in vivo effects of insulin on gene expression in adipose tissue in insulin-resistant and insulin-sensitive subjects. Diabetologia 49, 132-140 (2006).
25. Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419 (1985).
26. Angulo, P. et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45, 846-854 (2007).
27. Zelber-Sagi, S. et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J. Hepatol. 56, 1145-1151 (2012).
28. Adams, L. A., Sanderson, S., Lindor, K. D. & Angulo, P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol. 42, 132-138 (2005).
29. Sorrentino, P. et al. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. Am. J. Gastroenterol. 105, 336-344 (2010).
30. Ekstedt, M. et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44, 865-873 (2006).
31. Li, H. et al. High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China. J. Hepatol. 58, 557-563 (2013).
32. Wang, Y. et al. Association between metabolic syndrome and the development of non-alcoholic fatty liver disease. Exp. Ther. Med. 6, 77-84 (2013).
33. Zhou, Y. J., Li, Y. Y., Nie, Y. Q., Huang, C. M. & Cao, C. Y. Natural course of nonalcoholic fatty liver disease in southern China: a prospective cohort study. J. Dig. Dis. 13, 153-160 (2012).
34. Kim, C. W., Chang, Y., Sung, E., Shin, H. & Ryu, S. Serum ferritin levels predict incident non-alcoholic fatty liver disease in healthy Korean men. Metabolism 61, 1182-1188 (2012).
35. Sookoian, S. & Pirola, C. J. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 53, 1883-1894 (2011).
36. Liu, Y. L. et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat. Commun. 5, 4309 (2014).
37. Kotronen, A. et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 52, 1056-1060 (2009).
38. Luukkonen, P. K. et al. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD. J. Hepatol. (2017).
39. Luukkonen, P. K. et al. The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. J. Hepatol. 65, 1263-1265 (2016).
40. Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A. & Bacon, B. R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94, 2467-2474 (1999).
41. Greg J. Stanisz, et al. T1, T2 relaxation and magnetization transfer in tissue at 3T. Magnetic Resonance in Medicine 54(3), 507-512 (2005).
42. Graham, S. J., Stanisz, G. J., Kecojevic, A., Bronskill, M. J. & Henkelman, R. M. Analysis of changes in MR properties of tissues after heat treatment. Magn. Reson. Med., 42, 1061-1071 (1999).
43. Renata Longo, et al. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. Journal of Magnetic Resonance Imaging 5(3), 281-285 (1995).
44. Szczepaniak, L. S. et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am. J. Physiol. Endocrinol. Metab. 288, E462-8 (2005).
45. Szczepaniak, et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am.J.Physiol., 276, E977-89 (1999).
46. Thomsen, C. et al. Quantification of liver fat using magnetic resonance spectroscopy. Magn. Reson. Imaging 12, 487-495 (1994).
47. Wong, V. W. et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am. J. Gastroenterol. 107, 1862-1871 (2012).
48. DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837-845 (1988).